臨床婦人科産科72巻5号

2018年05月発行

今月の臨床 精子・卵子保存法の現在─「産む」選択肢をあきらめないために

配偶子保存法の周辺技術

ホルモン感受性悪性腫瘍患者へのレトロゾール併用による卵巣刺激

著者： 生水真紀夫¹

所属機関： ¹千葉大学大学院医学研究院生殖医学講座

ページ範囲：P.474 - P.478

文献概要

●乳がんなどのホルモン依存性がんの患者に対して卵巣刺激を実施する場合には，レトロゾールを併用して血中エストラジオール高値を避ける．

●卵巣刺激が乳がんの予後に影響を与えるというエビデンスは得られていない．

●排卵誘発でのレトロゾール使用は適応外使用である．

参考文献

1）Azim A, et al : Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil Steril 88 : 657─664, 2007

2）Kim SW, et al : A successful live birth with in vitro fertilization and thawed embryo transfer after conservative treatment of recurrent endometrial cancer. Gynecol Endocrinol 34 : 15─19, 2018

3）Rodgers RJ, et al : The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer : a systematic review. Hum Reprod 32 : 1033─1045, 2017

4）Domingo J, et al : Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 97 : 930─934, 2012

5）Checa Vizcaino MA, et al : The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online 24 : 606─610, 2012

6）Oktay K, et al : Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 91 : 3885─3890, 2006

7）Revelli A, et al : Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 29 : 993─996, 2013

8）Fahy UM, et al : In-vitro fertilization in completely natural cycles. Hum Reprod 10 : 572─575, 1995

9）Turan V, et al : Ovarian stimulation in patients with cancer : Impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci 25 : 26─32, 2018

10）Oktay K, et al : GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 20 : 783─788, 2010

11）Reddy J, et al : Triggering final oocyte maturation with gonadotropin-releasing hormone agonist（GnRHa） versus human chorionic gonadotropin（hCG） in breast cancer patients undergoing fertility preservation : an extended experience. J Assist Reprod Genet 31 : 927─932, 2014

12）Clemons M, et al : Estrogen and the risk of breast cancer. N Engl J Med 344 : 276─285, 2001

13）Kim J, et al : Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab 101 : 1364─1371, 2016

14）Biljan MM, et al : The outcome of 150 babies following the tratment with letrozole or letrole and gonadotropins. Fertil Steril 84 : S95, 2005

15）Tulandi T, et al : Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85 : 1761─1765, 2006

16）Legro RS, et al : Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 371 : 119─129, 2014

17）Sharma S, et al : Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS One 9 : e108219, 2014

18）Tatsumi T, et al : No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod 32 : 125─132, 2017

19）Forman R, et al : Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can 29 : 668─671, 2007